Clinical Trials Logo
  1. Home
  2. Cervical Cancer
  3. NCT03321448
  4. Details
NCT03321448 Clinical Trial

TMTP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer

Cervical Cancer Clinical Trial

Official title:
Novel Tumor Targeted Fluorescent TMTP1-ICG Mapping in Laparoscopic Sentinel Lymph Node Detection in Cervical Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03321448
Other study ID # TMTP1-ICG-01
Secondary ID
Status Recruiting
Phase Phase 1
First received October 23, 2017
Last updated October 25, 2017
Start date September 1, 2017
Est. completion date September 2019

Study information
Verified date October 2017
Source Huazhong University of Science and Technology
Contact Danhui Weng, Dr.
Phone 027-83663351
Email weng.dh@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

investigators aimed to determine the validity of our novel tumor targeted fluorescent TMTP1-ICG to increased accuracy of laparoscopic SLN mapping

Recruitment information / eligibility
Status Recruiting
Enrollment 40
Est. completion date September 2019
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- At least 18 years of age, married, without childbearing requirements at the time of consent.

- FIGO stage IA1-IIB cervical squamous cell cancer and is a candidate for laparoscopy intervention, with lymph node dissection being a part of the surgical plan.

- Subject has provided written informed consent.

Exclusion Criteria:

- Breast-feeding or pregnant

- Ongoing participation in another clinical trial with an investigational drug with 3 months

- Own allergy towards ICG and/or alcohol

- Diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases

- Patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• TMTP1-ICG
Detection of SLN
• ICG
Detection of SLN

Locations
Country Name City State
China Tongji Hospital, Tongji Medical Colledge, HUST Wuhan Hubei

Sponsors (1)
Lead Sponsor Collaborator
Huazhong University of Science and Technology

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Detection rate of sentinel lymph node Detection of sentinel lymph node per patient 1 day
Secondary Sensitivity Sensitivity of SLN mapping of TMTP1-ICG compared to the sensitivity of SLN mapping of ICG 7 days
Secondary Specificity Specificity of SLN mapping of TMTP1-ICG compared to the sensitivity of SLN mapping of ICG 7 days
Secondary Incidence of adverse events 7 days
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A